Posts for category: Recent News
Novel GABAA program targets hippocampal overactivity that leads to neurodegeneration and cognitive decline in Alzheimer’s disease patients Baltimore, MD, June 28, 2017 — AgeneBio, a pharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the Company has received an additional $750,000 grant from the Alzheimer’s Drug Discovery Foundation (ADDF). The grant…
Baltimore, MD, February 17, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at the Neuroscience BioPartnering & Investment Forum. CEO Jerry McLaughlin will present a overview of AgeneBio‘s work in neurodegeneration and its upcoming HOPE4MCI Phase 3 Trial on February 23 at 3:35 pm Eastern Time. The Neuroscience…
Baltimore, MD, February 2, 2016 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the company will present at BIO CEO & Investor Conference. CEO Jerry McLaughlin will present in the CNS/Neurological Track on Monday, February 8, at 10:15 am Eastern Time. The BIO CEO & Investor Conference is being held February 8 and…
Trial to Study AGB101 to Determine if it Can Slow Progression of Symptoms Associated with aMCI and Prevent or Delay Onset of Alzheimer’s Dementia Baltimore, MD, December 15, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the launch of the HOPE4MCI Phase 3 clinical trial website. Designed for…
Eli Lilly Alzheimer’s Drug Development Veteran Rounds Out Leadership Team for Phase 3 Ready AGB101 Baltimore, MD, December 8, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced the appointment of Alzheimer’s drug development veteran Richard Mohs, PhD, as Vice President of Clinical Development. Dr. Mohs offers more…
Baltimore, MD, November 24, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present on a panel at the Future of Innovation in Medicine Conference: Incentives for New Medical Treatments and Global Health next week. CEO Jerry McLaughlin will participate on a panel, entitled…
Baltimore, MD, November 11, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present as a “Top Project to Watch: Most Licensable Products in Neuroscience” at the Informa Therapeutic Area Partnering (TAP) conference, being held November 18 to 20 in Boston. CEO Jerry McLaughlin will present…
AGB101 formulation suitable for use in the upcoming HOPE4MCI Phase 3 clinical trial to slow the progression of aMCI, the symptomatic pre-dementia stage of Alzheimer’s disease Baltimore, MD, November 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced results of a crossover food effect study of its…
Scientific Leadership to Focus on Upcoming HOPE4MCI Phase 3 Trial and Proprietary AGB101 Formulation Baltimore, MD, October 22, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the 8th Clinical Trials on Alzheimer’s Disease (CTAD). The conference will be held November 5-7 in…
BALTIMORE, MD, October 6, 2015 — AgeneBio, a biopharmaceutical company developing innovative therapeutics for unserved patients battling neurodegeneration, today announced that the company will present at the BIO Investor Forum. The conference will be held October 20 to 21 at the Parc 55 San Francisco. CEO Jerry McLaughlin will present on Wednesday, October 21, at…
